ERBB2 and triple-negative breast carcinoma: The molecular subtypes were identical within the same patient in 310 (80.1%) of the 387 cases using the 2013 St Gallen standard, with 104 luminal A-like tumors, 93 luminal B-like (HER2−) tumors, 42 luminal B-like (HER2+) tumors, 39 HER2-enriched tumors, and 32 triple negative breast cancers (Table 3).